New drug combo aims to stop triple-negative breast cancer recurrence
NCT ID NCT03756298
First seen Apr 25, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tests whether adding atezolizumab (an immunotherapy) to capecitabine (a chemotherapy pill) works better than capecitabine alone in preventing breast cancer from returning. It involves 284 adults with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. The main goal is to see if the combination improves survival without the cancer coming back over 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Korea University, Guro hospital
Seoul, 08308, South Korea
Conditions
Explore the condition pages connected to this study.